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Antioxidant enzymes maintain cellular redox homeostasis. Manganese superoxide dismutase (MnSOD), an enzyme located in
mitochondria, is the key enzyme that protects the energy-generating mitochondria from oxidative damage. Levels of MnSOD are
reduced in many diseases, including cancer, neurodegenerative diseases, and psoriasis. Overexpression of MnSOD in tumor cells
can signiﬁcantly attenuate the malignant phenotype. Past studies have reported that this enzyme has the potential to be used as
an anti-inﬂammatory agent because of its superoxide anion scavenging ability. Superoxide anions have a proinﬂammatory role
in many diseases. Treatment of a rat model of lung pleurisy with the MnSOD mimetic MnTBAP suppressed the inﬂammatory
response in a dose-dependent manner. In this paper, the mechanisms underlying the suppressive eﬀects of MnSOD in
inﬂammatory diseases are studied, and the potential applications of this enzyme and its mimetics as anti-inﬂammatory agents
are discussed.
1.Introduction
Aerobic organisms utilize molecular oxygen (dioxygen; O2)
as the ﬁnal electron receptor in the oxidative phosphory-
lation electron transport chain. Normally, O2 is reduced
to H2O after receiving four electrons; however, partial
reduction of O2 leadstotheformationofhighlyreactiveoxy-
gen species (ROS), including the superoxide anion (O2
−·),
hydrogen peroxide (H2O2), and the hydroxyl radical (OH·).
ROS can damage lipids, proteins, and DNA, leading to aber-
rantdownstreamsignaling orstimulation ofapoptosis [1,2].
Oxidative stress has been implicated in neurodegenerative
diseases, aging, cancer, pulmonary ﬁbrosis, and vascular dis-
eases [3–6]; elimination of unwanted ROS is, therefore, very
important for organismal survival. To confront oxidative
stress caused by ROS, organisms have evolved a variety of
antioxidant enzymes, such as superoxide dismutase, catalase,
and glutathione peroxidase. However, ROS can also act as
cell signaling molecules and cause damage to foreign bodies
[2]. ROS are, therefore, double-edged swords with respect to
biological processes.
Inﬂammation is a host defense response to infectious
agents, injury, and tissue ischemia. Inﬂammation occurs
because of lymphocyte and macrophage invasion and the
secretion of mediators of inﬂammation such as cytokines,
cyclooxygenase products, and kinins [7]. Inappropriate
inﬂammation is a hallmark of various diseases. A large
body of evidence suggests that antioxidant enzymes are key
regulators of inﬂammation. Manganese superoxide dismu-
tase (MnSOD) is an enzyme present in mitochondria that
is one of the ﬁrst in a chain of enzymes to mediate the
ROS generated by the partial reduction of O2.M n S O D
has been implicated in a number of oxidative stress-related
diseases. In this paper, we will discuss the role of MnSOD
in various inﬂammation-associated diseases and explore the
therapeutic potentials of agents that regulate its expression.
2. Regulation of MnSOD
MnSOD mRNA levels can be upregulated by several fac-
tors: LPS [8], cytokines such as TNF [9], IL-1 [10], and2 Enzyme Research
VEGF [11], UVB irradiation, ROS [12], and thioredoxin
[13] .T h eh u m a nM n S O Dg e n e( sod2) has a housekeeping
promoter with multiple copies of Sp-1- and AP-2- binding
sequences. The promoter region also contains a GC-rich
region and NF-κB transcription regulation elements [14].
Several enhancers are also present in the promoter region
and in the second intron [15]. TNF and IL-1 inductions
of sod2 mRNA require a 238-bp TNF response element
(TNFRE), which is located in intron 2. Both C/EBP and
NF-κB bind to the TNFRE enhancer to interact with the
sod2 promoter, resulting in the upregulation of MnSOD
transcription [9]. TPA-induced MnSOD expression is due
to the transcription factor speciﬁcity protein 1- (SP1-)
mediated PKC signaling [16]. Dimeric SP1 can bind to GC-
rich sequences of GGGCGG, but the binding aﬃnity and
transcription properties vary according to the interacting
cofactors [17–19].
The downregulation of mRNA levels is as important in
b i o l o g i c a lp r o c e s s e sa si su p r e g u l a t i o n .B e c a u s eR O Sc a na c t
as intracellular secondary messengers, maintaining proper
levels of these molecules is important for normal cellular
function. This suggests that antioxidant enzymes are likely
maintained at low levels in cells.
Many studies have reported the downregulation of
MnSODmRNAlevelsindiseasestates.Manytumorcelllines
have mutations in the promoter region of the MnSOD gene
that increase the number of AP-2-binding sites. AP-2 can
interact with SP-1 within the promoter region and decrease
promoter activity, thus downregulating transcription [17].
VEGF can upregulate MnSOD mRNA levels through the
ROS-sensitive PKC-NF-κB and PI3K-Akt-Forkhead signal-
ing pathways [11]. FOXO3a is a member of the Forkhead
family of transcription factors. Phosphorylation of Ser253
of FOXO3a decreases DNA binding and consequently gene
expression, which results in the age-related activation of Akt
[18].
Aging-related disorders are often associated with oxida-
tive stress. Epigenetic silencing of the MnSOD gene has also
been observed in human breast cancers. Both DNA methy-
lation and histone modiﬁcation contribute to this regulation
[19]. Epigenetic modiﬁcation inﬂuences the abilities of SP1,
AP-1, and NF-κB to bind to cis-elements in the promoter
region of the MnSOD gene, resulting in silencing of this
gene.
MnSOD mRNA upregulation always results in increased
levels of MnSOD protein [20]. MnSOD is located in mito-
chondria; therefore, its major role appears to be controlling
the levels of O2
−· in mitochondria. H2O2 is a product
of MnSOD-catalyzed reactions; increased MnSOD activity
results in H2O2 accumulation. H2O2 can act as a second
messenger or as a Fenton reaction agent, thereby causing
damage to cells. To elucidate the signiﬁcance of MnSOD
regulation, the function of MnSOD must be considered.
3. The Function of MnSOD
In cancer cells, MnSOD is almost always suppressed by cer-
tain transcription factors or through epigenetic modiﬁcation
of cis-elements or chromatin. Overexpression of MnSOD in
cancer cells can alter the phenotype in culture; the cells lose
theabilitytoformcolonies,atraitcharacteristicofmalignant
cells [21]. A large number of studies have reported that ROS
play an important role in tumor metastasis [22, 23]. ROS can
activate cell signaling pathways and/or mutate DNA, thereby
promoting tumor proliferation and metastasis. This may
explainwhytumorcellsalmostalwaysexpressMnSODatlow
levels.ExogenousMnSODcanblockROSsignalingtoinhibit
tumorigenesis, suggesting that MnSOD may be a potential
antitumor therapeutic target. Overexpression of MnSOD
can enhance the activity of the superoxide-sensitive enzyme
aconitase and inhibit pyruvate carboxylase activity, thereby
altering the metabolic ability of the cell and inhibiting cell
growth [24].
A mouse knockout model of manganese superoxide dis-
mutase has proven to be a useful model for elucidating the
functionofMnSOD.Asstatedpreviously,themajorfunction
of MnSOD is to protect mitochondria from ROS damage.
However,althoughROScandamageorganisms,theyarealso
mediators of cell signaling. Developing mice fetuses lacking
manganese superoxide dismutase do not survive to birth;
overexpressions of other types of SOD cannot attenuate
this symptom [25]. Newlyborn MnSOD knockout mice
have extensive mitochondrial injuries in multiple tissues.
Disorders such as Leigh’s disease and Canavan disease are
characterizedbymitochondrial abnormalities.Reductionsin
the levels of a variety of energy metabolism enzymes, espe-
ciallythose with a role in the TCA cycle, have also been noted
in these disorders. Treatment of Sod2tm1cje(−/−)m u t a n t
mice with the manganese superoxide dismutase mimetic
manganese 5,10,15,20-tetrakis (4-benzoic acid) porphyrin
(MnTBAP)improvedthesemiceanddramaticallyprolonged
their survival times [26–28].
Miki et al. studied the cytological diﬀerences between
wild-type mice and heterozygous sod2 knockout (sod2
−/+) mice after permanent focal cerebral ischemia (FCI).
Cytochrome c accumulated at an early stage and was
signiﬁcantly more elevated in sod2 −/+ mice than it was in
wild-typemice.AremarkableincreaseinDNAladderingwas
also observed in the sod2 −/+ mice but not in the wild-
type mice, suggesting that MnSOD can block the release of
cytosolic cytochrome c and prevent apoptosis [29]. Neuro-
toxinssuchas1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
(MPTP), 3-nitropropionic acid (3-NP), and malonate are
commonly used in neurodegenerative functional models.
Mice with a partial deﬁciency in MnSOD are more sensitive
to these mitochondrial toxins than are normal mice [30],
suggesting that MnSOD is an antitoxin agent that scavenges
free radicals generated by environmental toxins that may
cause neurodegeneration.
MCF-7 human carcinoma cells exposed to single-dose
radiation and radioresistant variants isolated from MCF-7
cells following fractionated ionizing radiation (MCF and FIR
cells) were found to possess elevated MnSOD mRNA levels,
activity, and immunoreactive proteins. MnSOD-silenced
cells were sensitive to radiation. The genes P21, Myc, 14-3-3
zeta, cyclin A, cyclin B1, and GADD153 were overexpressedEnzyme Research 3
in both MCF + FIR and MCF + SOD cells (MCF-7 cells
overexpressing MnSOD). These genes were suppressed in
Sod2 knockout mice (−/−) and in MnSOD-silenced cells
[31]. These six genes are survival genes [32–34] that protect
cell from radiation-induced apoptosis.
4. MnSOD in Diseaseswith Inﬂammation
Inﬂammation is a complex response to harmful stimuli,
such as tissue injury, pathogens, autoimmune damage,
ischemia and other irritants [35]. Numerous inﬂammation-
associated molecules and cells remove injurious stimuli and
repair damaged tissues. The healing process includes the
destruction of “foreign objects” and the repair of injured
self-tissues. If targeted destruction and associated repair
are not correctly programmed, inﬂammatory disorders
resulting in diseases such as psoriasis, inﬂammatory bowel
disease, and neurodegenerative diseases develop [36, 37].
Superoxide anions have proinﬂammatory roles, causing lipid
peroxidation and oxidation, DNA damage, peroxynitrite
ion formation, and recruitment of neutrophils to sites of
inﬂammation [38–40]. Elimination of superoxide anions by
MnSOD and its isoenzymes can, therefore, be considered to
be anti-inﬂammatory (Figure 1).
Inﬂammatory bowel disease (IBD) is accompanied by
the excessive productions of reactive oxygen and nitrogen
metabolites [41]. The concentration of malondialdehyde
(MDA), which can serve as an index for lipid peroxidation,
was found to be increased in inﬂamed mucosa cells [42].
Lipid peroxidation is associated with hydroxyl radicals and
superoxide anions. In inﬂamed cells, levels of MnSOD are
suppressed relative to those of normal cells, indicating that
MnSODmaybeatherapeutictarget.NOD2isasusceptibility
gene for IBD; the NOD2 protein can activate the immune
system by triggering NF-κB and can negatively regulate
the Toll-like receptor-mediated T-helper type 1 response,
thereby increasing susceptibility to infection [43, 44]. The
pathology of IBD requires further investigation. Currently,
drugs targeting NF-κB or ROS have been found to be
somewhat eﬀective.
The skin is the largest organ of the human body and
acts as a physical boundary to protect the internal organs
against the environment. Skin dysfunction could result
in injury to deeper tissues. Skin injuries can activate the
acute inﬂammatory response, and infection can heighten
this response. Psoriasis is a chronic disease characterized
by inﬂamed, scaly, and frequently disﬁguring skin lesions.
Epidermal keratinocytes in this disease show altered diﬀer-
entiation and hyperproliferation, and immune cells such as
T-cells and neutrophils are present at lesion sites [45]. JunB
is a component of the AP-1 transcription factor complex
that regulates cell proliferation, diﬀerentiation, the stress
response, and cytokine expression [46]. Both JunB and c-Jun
are highly expressed in lesional skin, but levels of JunB have
been shown to be low in severe psoriasis and intermediate
in mild psoriasis, while c-Jun is expressed in the opposite
manner [47].
Most components of the AP-1 transcription factor
are redox-sensitive proteins regulated by ROS signaling.
Exposure of keratinocytes to chemical irritants, allergens,
or inﬂammatory stimuli triggers activation of several stress-
sensitive protein kinases that are mediated by ROS. ROS
enhance EGFR phosphorylation and activate ERKs and JNKs
[48]. ROS also activate NF-κB during skin inﬂammation.
These ﬁndings indicate that antioxidant enzymes may have
potential as therapeutic agents.
MnSOD was found to be highly expressed in psoriasis,
but this expression was not associated with the pathology
of psoriasis [49]. A reasonable hypothesis is that lesional
skin cells are induced to express MnSOD by cytokines
released from inﬂammatory cells in order to counteract
inﬂammation-induced oxidative stress. Although native
MnSOD has shown promising anti-inﬂammatory properties
against many diseases in both preclinical and clinical studies,
there are several drawbacks to using native MnSOD as a
therapeutic agent and pharmacological tool. Low molecular
weight mimetics of SOD were, therefore, developed to
a d d r e s ss o m eo ft h ed r a w b a c k so fn a t i v eS O Du s e .
To date, frequently used SOD mimetics are MnTBAP,
the Mn(III)-salen complex, and Mn II-pentaazamacrocyclic
ligand-based SOD mimetics [50]. In a mouse model
of lung pleurisy, treatment with MnTBAP before car-
rageenan administration was found to suppress inﬂamma-
tory responses in a dose-dependent manner [51]. The mech-
anism of attenuation of inﬂammation by SOD mimetics
is the reduction of peroxynitrite formation through the
eliminationofsuperoxideanionsbeforetheyreactwithnitric
oxide. Because peroxynitrites are numerous and have pro-
inﬂammatory and cytotoxic eﬀects, administration of SOD
mimetics is clinically very important. M40403 (Figure 2)w a s
derivedfrom1,4,7,10,13-pentaazacyclopentadecanecontain-
ing added bis(cyclohexylpyridine) functionalities. It is the
best products achieved high stability and catalytical activity
based on the computer-aided design. M40403 gets a high
speciﬁcity for scavenging superoxide anion, while other
oxidants, such as hydrogen peroxide, peroxynitrite, and
hypochlorite, are hardly oxidative to Mn-II packaged in
the complex. The biological function of M40403 has been
tested in several models [52]. The global mechanism seems
that M40403 could block nitrosation of tyrosine in pro-
teins, indicating that superoxide anion driven formation
of peroxynitrite might be responsible for the nitrosation.
While increasing evidences are suggesting that nitrosation
plays important role in many inﬂammation-related diseases
[50, 53], this low molecular mass synthetic is a potential
therapeutic agent for curing inﬂammation.
5. Conclusions
Inﬂammation is a traditional but complex problem that still
requires extensive investigation. ROS play a very important
role in the triggering and promotion of inﬂammation. Thus,
antioxidant enzymes that can function as ROS scavengers are
ideal therapeutic agents. Data generated from mouse models
have shown that native MnSOD has anti-inﬂammatory
properties but also some practical disadvantages. MnSOD
mimetics were, therefore, developed to address the short-






















Figure 1: Biological basis and eﬀects of superoxide generation. Excessive production of superoxide anions can lead to inﬂammation through














Figure 2: The three-dimensional (3D) structure of human manganese superoxide dismutase (a) and that of the synthetic superoxide dismu-
tase mimetic M40403 (b). The 3D structure of M40403 and the active site of MnSOD (c). This manganese-containing biscyclohexylpyridine
has superior catalytic activity compared to that of the native enzyme. Note that Mn2+ is purple and Cl− is light green in the 3D structure of
M40403.Enzyme Research 5
molecules have been tested in several in vivo and in vitro
models; they have all been shown to be eﬀective mimics of
SOD. Despite the great achievements made over the past few
decades, however, there is still a need to develop even more
eﬃcient and compatible anti-inﬂammatory agents suitable
for clinical pharmaceutical therapy.
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